Source comparison
Hexarelin vs Tesamorelin Better Comparison: Research Application Matrix
GH Peak Amplitude 42.3 ng/mL mean (340% above baseline) 18.7 ng/mL mean (180% above baseline) Hexarelin produces higher peaks but risks receptor desensitisation with chronic use Visceral Fat Reduction Not FDA-approved; minimal data on VAT-specific effects FDA-
This comparison does not assign a generated winner or score.
- GH Peak Amplitude
- 42.3 ng/mL mean (340% above baseline)
- 18.7 ng/mL mean (180% above baseline)
- Hexarelin produces higher peaks but risks receptor desensitisation with chronic use
- Visceral Fat Reduction
- Not FDA-approved; minimal data on VAT-specific effects
- FDA-approved 15.2% VAT reduction at 26 weeks
- Tesamorelin demonstrates superior visceral fat targeting through GHRH pathway
- Dosing Frequency
- 2–3× weekly (to avoid tachyphylaxis)
- Daily dosing without desensitisation through 52 weeks
- Tesamorelin allows consistent daily protocols; hexarelin requires cycling
- Receptor Mechanism
- Dual agonist (GHS-R1a + CD36)
- GHRH receptor-specific
- Hexarelin's ghrelin pathway adds appetite stimulation; tesamorelin avoids orexigenic effects
- Cardioprotective Effects
- 28% infarct size reduction in ischemia models
- No direct cardioprotective data
- Hexarelin shows CD36-mediated cardiac benefits tesamorelin doesn't replicate
- Plasma Half-Life
- 70–90 minutes
- 26 minutes (but extended receptor occupancy)
- Half-life alone doesn't predict efficacy. Receptor kinetics matter more